A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJOGREN'S SYNDROME (PSS)

Authors
Category Primary study
JournalANNALS OF THE RHEUMATIC DISEASES
Year 2019
This article has no abstract
Epistemonikos ID: 0133e88bbc944a58cadd5101b564c400da19076f
First added on: Feb 11, 2025